Drugs containing Strontium Chloride Sr 89: Metastron
Strontium Chloride Sr 89 Levels and Effects while Breastfeeding
Summary of Use during Lactation
Information in this record refers to the use of strontium 89 as a therapeutic agent. No information is available on the therapeutic use of strontium 89 during breastfeeding. It has been estimated that about 9% of the strontium in the maternal bloodstream reaches breastmilk for another strontium isotope, strontium 90.[1] Because strontium can substitute for calcium in infant bones, the manufacturer and expert opinion recommend discontinuing breastfeeding before a nursing mother receives strontium 89 chloride.[2]
Drug Levels
Strontium 89 decays by beta emission with a physical half-life of 50.5 days.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Harrison JD, Smith TJ, Phipps AW. Infant doses from the transfer of radionuclides in mothers' milk. Radiat Prot Dosimetry 2003;105:251-6. [PubMed: 14526966]
2.
Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934-40. [PubMed: 18649080]
Substance Identification
Substance Name
Strontium Chloride Sr 89
CAS Registry Number
38270-90-5
Drug Class
Breast Feeding
Lactation
Milk, Human
Radiopharmaceuticals
Strontium Radioisotopes
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.